ArticleImmunity & ageing : I & A2026
Immunoinflammatory biomarkers for sepsis-associated acute kidney injury: a multicenter prospective cohort study.
Article in Immunity & ageing : I & A, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundImmune dysregulation is central to sepsis-related organ injury, yet standard clinical indicators show limited predictive value for sepsis-associated acute kidney injury (SA-AKI) in older adults(aged ≥ 65 years). This study evaluated whether immuno-inflammatory biomarkers improve early prediction of SA-AKI.
methodsIn this prospective multicenter cohort of 627 older adults with sepsis admitted to ICUs in five Beijing tertiary hospitals, the overall incidence of SA-AKI was 43.1% (270/627). Clinical variables and immune-inflammatory markers collected within 24 h were used to construct a clinical model (Model 1) and an integrated model (Model 2, combining clinical variables with immuno-inflammatory biomarkers). Model performance was examined using ten-fold cross-validation and an internal test set.
resultsSix clinical predictors were included in Model 1, while Model 2 additionally incorporated C3, C4, CD4% T cells, and NK cells. In the testing set, Model 2 showed markedly better discrimination than Model 1 (AUC 0.878 vs. 0.717; p < 0.001) with higher sensitivity and specificity. Immune-marker inclusion significantly improved risk reclassification (NRI 86.1%; p = 0.002).
conclusionsAdding immuno-inflammatory biomarkers substantially enhanced early prediction of SA-AKI in older adults, underscoring the key role of immune imbalance and supporting targeted immune monitoring for individualized risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.